ROLE OF LHRH ANALOGUE IN CASES OF REFRACTORY MASTALGIA.

In: INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · 2022 · pp. 17–18 · doi:10.36106/ijsr/0406569 · W4313442390
article OA: closed CC0
View on OpenAlex View at publisher

Abstract

Background: Mastalgia is the commonest cause of visit to the breast clinic. The present study was conducted to assess the efcacy of complete estrogen blockade (CEB) with centchroman and LHRH analog goserelin in the treatment of refractory mastalgia. Aim: To study the effect of LHRH analogue in refractory mastalgia and to increase pain free period in patients with refractory mastalgia. Methods: This is a prospective cohort study conducted in the Dept.Of Gen.Surgery IGIMS ,Patna over a period of six months.The reduction of pain score ( as measured by a visual analog scale (VAS) recorded on a breast pain chart ) to 3 or less at 6 weeks of initiation of treatment was taken as primary objective. Results: Fifty patients were enrolled in the study. The mean age of the patients was 28 years (15–45 years). The median duration of symptoms was 6 months (4–8). All of them had bilateral mastalgia. The mean pain score at start of study was 7. Conclusion: Complete estrogen blockade by means of GNRH analogue is safe and effective for treatment of refractory mastalgia.

My notes (saved in your browser only)

Outcome instruments

VAS-pain

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (5)

Source provenance

openalex
last seen: 2026-05-10T10:25:57.662601+00:00
License: CC0 · commercial use OK